MeiraGTx   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03278873
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

MeiraGTx UK II Ltd